Routine

Monoclonal gammopathy of undetermined significance (MGUS; incl. smouldering myeloma triage)

Plasma cell disorder · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Asymptomatic monoclonal paraprotein (<30 g/L), clonal plasma cells <10% in marrow, and NO myeloma-defining end-organ damage (no CRAB). Common incidental finding; ~1%/year progression to myeloma/lymphoma/amyloidosis. ED role: distinguish benign MGUS from active myeloma by screening for CRAB features, and refer for surveillance.

Figures & algorithms

Rouleaux
Rouleaux

Red flags

  • Bone pain / pathological fracture / lytic lesions
  • Hypercalcaemia
  • Unexplained renal impairment (cast nephropathy)
  • Anaemia or other cytopenias
  • Recurrent infections
  • Features of amyloidosis (nephrotic syndrome, cardiac failure, neuropathy, macroglossia) - needs urgent referral

Assessment

Differential diagnosis

  • Multiple myeloma (end-organ damage / CRAB, or myeloma-defining biomarkers)
  • Smouldering (asymptomatic) myeloma (paraprotein >=30 g/L or plasma cells 10-60%, no CRAB)
  • Waldenstrom macroglobulinaemia (IgM)
  • AL amyloidosis / light chain deposition
  • Reactive polyclonal gammopathy (infection, inflammation, liver disease)

Investigations

  • Serum protein electrophoresis + immunofixation (identify and quantify paraprotein, type)
  • Serum free light chains + ratio
  • FBC (anaemia), U&E + corrected calcium, albumin (CRAB screen)
  • 24h urine / urine electrophoresis for Bence-Jones protein
  • Skeletal review only if symptomatic/red flags (whole-body MRI or low-dose CT if myeloma suspected, not needed for low-risk MGUS)
  • LDH, beta-2 microglobulin if progression suspected

Management

  • Screen for CRAB: hyperCalcaemia, Renal impairment, Anaemia, Bone lesions - any present means NOT MGUS, investigate for myeloma
  • Confirm paraprotein <30 g/L, no CRAB, and no myeloma-defining biomarker
  • Risk-stratify (non-IgG type, paraprotein >=15 g/L, abnormal free light chain ratio = higher risk)
  • No treatment for MGUS - surveillance only
  • Arrange follow-up monitoring (paraprotein + bloods) - interval per risk (e.g. 6 months then annually)
  • Safety-net: advise re-presentation with bone pain, infections, symptoms of hypercalcaemia/renal failure
  • Refer to haematology (low-risk may be GP-monitored per local pathway)

Drugs & doses

No specific treatment for MGUS - surveillance only
Treat any incidentally found complication on its own pathway (e.g. hypercalcaemia, renal impairment -> then investigate as myeloma)

Disposition

Outpatient - haematology referral for risk stratification and surveillance. Admit only if a red flag reveals active myeloma or end-organ complication.

Complications & pitfalls

  • Progression to multiple myeloma / smouldering myeloma
  • Waldenstrom macroglobulinaemia / lymphoma
  • AL amyloidosis
  • MGRS (monoclonal gammopathy of renal significance) - kidney damage despite low burden

Exam pearls

  • MGUS is a diagnosis of exclusion - the job in ED is to rule out CRAB/myeloma, not to treat
  • Any CRAB feature upgrades the diagnosis and mandates myeloma workup
  • Remember MGRS and AL amyloidosis - a small paraprotein can still cause major renal/cardiac damage
  • IgM MGUS can progress to Waldenstrom/lymphoma rather than myeloma
  • Do not over-image low-risk MGUS; do fully image if any red flag

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.